KRAS is often altered in pancreatic carcinoma, colorectal tumors and lung malignancies and HRAS mutations are common in dermatological malignancies and head and neck cancers whereas NRAS alterations in melanomas and in hematopoietic malignancies. Here, HRAS is linked to melanoma.